NDC properties for "Simlandi 40 MG per 0.4 ML Auto-Injector" (RxCUI 2677787)
About this data
The tables show NDC propoerties for Simlandi 40 MG per 0.4 ML Auto-Injector with the RxCUI 2677787
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for Simlandi 40 MG per 0.4 ML Auto-Injector (RxCUI 2677787)
| BLA | BLA761299 |
|---|---|
| MMSL_CODE | BD40449 |
| RxCUI | 2677787 |
| SPL_SET_ID | 12f609c9-2088-bb05-e063-6394a90a9ecc |
| Prescribable Synonym | Simlandi 40 MG in 0.4 ML Auto-Injector |
| RXNAV_STR | Simlandi 40 MG per 0.4 ML Auto-Injector |
| RxNorm Name | 0.4 ML adalimumab-ryvk 100 MG/ML Auto-Injector [Simlandi] |
| RxNorm Synonym | Simlandi 40 MG per 0.4 ML Auto-Injector |
| Related queries | Interactions (for RxCUI 2677787) |
NDC Properties
NDC Item 51759040202
| NDC 9 | 51759-402 |
|---|---|
| NDC 10 | 51759-402-02 |
| NDC Item | 51759040202 |
| Packaging | 2 KIT in 1 CARTON (51759-402-02) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .4 mL in 1 SYRINGE (51759-513-21) * .4 mL in 1 POUCH (65517-0002-1) |
| BLA | BLA761299 |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2024-05-20 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 51759-402 |
NDC Item 51759040217
| NDC 9 | 51759-402 |
|---|---|
| NDC 10 | 51759-402-17 |
| NDC Item | 51759040217 |
| Packaging | 1 KIT in 1 CARTON (51759-402-17) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .4 mL in 1 SYRINGE (51759-513-21) * .4 mL in 1 POUCH (65517-0002-1) |
| BLA | BLA761299 |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2024-05-20 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 51759-402 |
NDC Item 51759051321
| NDC 9 | 51759-513 |
|---|---|
| NDC 10 | 51759-513-21 |
| NDC Item | 51759051321 |
| Packaging | 0.4 mL in 1 SYRINGE |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG LABEL |
| Related queries | Properties for NDC 9 51759-513 |
NDC Item 51759040202
| NDC 9 | 51759-402 |
|---|---|
| NDC 10 | 51759-402-02 |
| NDC Item | 51759040202 |
| Packaging | 2 KIT in 1 CARTON (51759-402-02) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .4 mL in 1 SYRINGE (51759-513-21) * .4 mL in 1 POUCH (65517-0002-1) |
| BLA | BLA761299 |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2024-05-20 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 51759-402 |
NDC Item 51759040217
| NDC 9 | 51759-402 |
|---|---|
| NDC 10 | 51759-402-17 |
| NDC Item | 51759040217 |
| Packaging | 1 KIT in 1 CARTON (51759-402-17) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .4 mL in 1 SYRINGE (51759-513-21) * .4 mL in 1 POUCH (65517-0002-1) |
| BLA | BLA761299 |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2024-05-20 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 51759-402 |
NDC Item 51759051321
| NDC 9 | 51759-513 |
|---|---|
| NDC 10 | 51759-513-21 |
| NDC Item | 51759051321 |
| Packaging | 0.4 mL in 1 SYRINGE |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG LABEL |
| Related queries | Properties for NDC 9 51759-513 |
NDC Item 51759040202
| NDC 9 | 51759-402 |
|---|---|
| NDC 10 | 51759-402-02 |
| NDC Item | 51759040202 |
| Packaging | 2 KIT in 1 CARTON (51759-402-02) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .4 mL in 1 SYRINGE (51759-513-21) * .4 mL in 1 POUCH (65517-0002-1) |
| BLA | BLA761299 |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2024-05-20 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 51759-402 |
NDC Item 51759040217
| NDC 9 | 51759-402 |
|---|---|
| NDC 10 | 51759-402-17 |
| NDC Item | 51759040217 |
| Packaging | 1 KIT in 1 CARTON (51759-402-17) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .4 mL in 1 SYRINGE (51759-513-21) * .4 mL in 1 POUCH (65517-0002-1) |
| BLA | BLA761299 |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Marketing effective time low | 2024-05-20 |
| Marketing status | ACTIVE |
| Related queries | Properties for NDC 9 51759-402 |
NDC Item 51759051321
| NDC 9 | 51759-513 |
|---|---|
| NDC 10 | 51759-513-21 |
| NDC Item | 51759051321 |
| Packaging | 0.4 mL in 1 SYRINGE |
| Labeler | Teva Pharmaceuticals USA, Inc. |
| Label type | HUMAN PRESCRIPTION DRUG LABEL |
| Related queries | Properties for NDC 9 51759-513 |